<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601119</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200136_550</org_study_id>
    <nct_id>NCT01601119</nct_id>
  </id_info>
  <brief_title>Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients</brief_title>
  <official_title>The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono Limited, UK</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to establish the impact of current disease modifying therapies (DMTs) and
      associated support services on Patient Reported Experience Measures and Patient Reported
      Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the
      United Kingdom (UK).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Satisfaction</measure>
    <time_frame>96 weeks</time_frame>
    <description>The survey sample size has been calculated based on the TSQM-9 questionnaire in order to compare scores between both patient cohorts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Work Productivity</measure>
    <time_frame>96 weeks</time_frame>
    <description>Work Productivity and Activity Impairment (WPAI) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>96 weeks</time_frame>
    <description>Multiple Sclerosis Impact Scale (MSIS-29) v2.0 Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life EuroQoL (EQ-5D)-5L Questionnaire</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device satisfaction</measure>
    <time_frame>96 weeks</time_frame>
    <description>Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ) is an MS-specific treatment satisfaction questionnaire that evaluates injection system satisfaction and side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of support services</measure>
    <time_frame>96 weeks</time_frame>
    <description>Patient evaluation of Manufacturer, Homecare and NHS support services</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">545</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Rebif cohort</arm_group_label>
    <description>Subject will receive Rebif as the treatment medication as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other DMT cohort</arm_group_label>
    <description>Subjects will receive DMT other than Rebif as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebif</intervention_name>
    <description>The subjects will receive Rebif as per the current practices or as directed by the physician.</description>
    <arm_group_label>Rebif cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Other: Disease modifying therapies (DMT)</intervention_name>
    <description>The subjects will receive other DMTs as per the current practices or as directed by the physician.</description>
    <arm_group_label>Other DMT cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in the UK newly diagnosed with RMS (and naive to previous DMT) and receiving a DMT
        that can be self-administered
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing Multiple Sclerosis patients aged 18 years or over.

          -  Naive to previous DMT therapy and not yet started treatment with a disease modifying
             therapy.

        Exclusion Criteria:

          -  Participating in an MS-related clinical trial.

          -  Unwilling to provide electronic online consent.

          -  Any disability that may impair them from being able to complete the online
             questionnaire.

          -  Do not have regular access to the Internet.

          -  Unable to complete the baseline questionnaire before they receive their first DMT
             injection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono Limited, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Please contact the</name>
      <address>
        <city>Merck KGaA Communication Center for locations</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Patient reported outcome</keyword>
  <keyword>Patient reported experience</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

